Baxter International Inc (NYSE: BAX) is a medical products company that develops, manufactures, and sells hospital and renal care products used in acute and chronic care settings. Revenue is generated through the direct sale of medical devices, intravenous therapies, pharmaceuticals, and nutritional products to hospitals, clinics, and other healthcare providers. As of its 10-K filed February 12, 2026, Baxter completed a significant portfolio restructuring, selling its Kidney Care business (now Vantive Health LLC) to Carlyle Group affiliates on January 31, 2025 for approximately $3.71 billion in pre-tax cash proceeds. Baxter used the net after-tax proceeds, along with other sources, to repay $3.81 billion in legacy indebtedness during FY2025. The Kidney Care segment is reported as discontinued operations in Baxter's FY2025 consolidated financials, meaning the continuing business is now focused on its remaining hospital products and therapies segments.
Source: SEC 10-K, filed 2026-02-12
Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Becton Dickinson and Co Boston Scientific Corp Edwards Lifesciences Corp Dexcom Inc HOLOGIC INC IDEXX Laboratories Inc Insulet Corp Resmed Inc Zimmer Biomet Holdings, Inc
Loading...
